Abstract
CD38 is regarded as a potential target. Inhibitors against CD38 can regulate calcium metabolism in human body to impede the occurrence of disease, including diabetes and myeloma. In this work, 47 thiazoloquin(az)olin(on)es analogues with high pIC50 values in the micromolar ranges are studied by three-dimensional quantitative structure-activity relationship (3D-QSAR) and molecular docking. The comparative molecule field analysis (i.e., CoMFA q2 = 0.790; r2 = 0.967; rpred 2 = 0.872) and comparative molecular similarity indices analysis (i.e., CoMSIA q2 = 0.723; r2 = 0.969; rpred 2 = 0.815) are applied. Then, the Topomer CoMFA method is performed to validate these models, and the results show that this model has q2 = 0.662, r2 = 0.915 and rpred 2 = 0.704. These results indicate that the three models have good predictive abilities. Subsequently, molecular docking highlights the important interactions between the ligand and the CD38 receptor protein.
Keywords: 3D-QDAR, docking, CD38 inhibitor, Topomer CoMFA, CoMFA, CoMSIA
Letters in Drug Design & Discovery
Title:Identification of Thiazoloquin(az)olin(on)es Derivatives as CD38 Inhibitors Through 3D-QSAR and Molecular Docking Simulations
Volume: 14 Issue: 2
Author(s): Xiaodong Gao and Yujie Ren
Affiliation:
Keywords: 3D-QDAR, docking, CD38 inhibitor, Topomer CoMFA, CoMFA, CoMSIA
Abstract: CD38 is regarded as a potential target. Inhibitors against CD38 can regulate calcium metabolism in human body to impede the occurrence of disease, including diabetes and myeloma. In this work, 47 thiazoloquin(az)olin(on)es analogues with high pIC50 values in the micromolar ranges are studied by three-dimensional quantitative structure-activity relationship (3D-QSAR) and molecular docking. The comparative molecule field analysis (i.e., CoMFA q2 = 0.790; r2 = 0.967; rpred 2 = 0.872) and comparative molecular similarity indices analysis (i.e., CoMSIA q2 = 0.723; r2 = 0.969; rpred 2 = 0.815) are applied. Then, the Topomer CoMFA method is performed to validate these models, and the results show that this model has q2 = 0.662, r2 = 0.915 and rpred 2 = 0.704. These results indicate that the three models have good predictive abilities. Subsequently, molecular docking highlights the important interactions between the ligand and the CD38 receptor protein.
Export Options
About this article
Cite this article as:
Gao Xiaodong and Ren Yujie, Identification of Thiazoloquin(az)olin(on)es Derivatives as CD38 Inhibitors Through 3D-QSAR and Molecular Docking Simulations, Letters in Drug Design & Discovery 2017; 14 (2) . https://dx.doi.org/10.2174/1570180813666160919121104
DOI https://dx.doi.org/10.2174/1570180813666160919121104 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Defining Carbohydrate Antigens as HIV Vaccine Candidates
Current Pharmaceutical Design Potential Role of TRP Channels in Cough Hypersensitivity?
Current Respiratory Medicine Reviews An Interventional Pulmonologist’s Tool: Endobronchial Ultrasound- Guided Transbronchial Needle Aspiration (EBUS-TBNA) in Thoracic Disease — An Update
Current Respiratory Medicine Reviews Editorial (Thematic Issue: Drug Delivery Australia)
Current Drug Delivery Editorial: Comparison of Forgotten Surgical Techniques for Pulmonary Tuberculosis
Current Respiratory Medicine Reviews Sulphur-Containing Heterocycles as Antimycobacterial Agents: Recent Advances in Thiophene and Thiadiazole Derivatives
Current Topics in Medicinal Chemistry The Physiology of Nitric Oxide: Control and Consequences
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Antiviral Activity and Molecular Targets of Plant Natural Products Against Avian Influenza Virus
Current Organic Chemistry Drug Design for Neglected Disease in Brazil
Mini-Reviews in Medicinal Chemistry Molecular Docking Study for Analyzing the Inhibitory Effect of Anti-inflammatory Plant Compound Against Tumour Necrosis Factor (TNF-α)
Current Drug Therapy New Insights in Design and Development of Antitubercular Drugs
Current Bioactive Compounds Recent Developments in Oral Bait Vaccines for Wildlife
Recent Patents on Drug Delivery & Formulation Immune System Induction of Nerve Growth Factor in an Animal Model of Multiple Sclerosis: Implications in Re-Myelination and Myelin RepairATION AND MYELIN REPAIR
CNS & Neurological Disorders - Drug Targets The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design NMR Based Metabolomics: An Exquisite and Facile Method for Evaluating Therapeutic Efficacy and Screening Drug Toxicity
Current Topics in Medicinal Chemistry Targeting the Formation of the Cell Wall Core of M. tuberculosis
Infectious Disorders - Drug Targets Molecular Interactions in Interleukin and Toll-like Receptor Signaling Pathways
Current Pharmaceutical Design HIV Genetic Diversity: Biological and Public Health Consequences
Current HIV Research Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period
Current Clinical Pharmacology